Stroke Etiology Does Not Alter Bridging Thrombolysis Efficacy

Mechanical thrombectomy is the established standard for treating acute ischemic stroke caused by large vessel occlusion, significantly improving functional independence compared to medical management alone [1, 2]. However, the clinical utility of administering intravenous thrombolysis (the use of pharmacological agents to dissolve a clot) before the procedure remains a subject of active debate, particularly for patients presenting directly to specialized centers [3, 4]. While bridging therapy may facilitate early recanalization, it also carries a potential risk of symptomatic intracranial hemorrhage (bleeding within the skull that is associated with clinical deterioration) [5, 6]. Current guidelines generally support the use of thrombolytics in eligible patients, yet there is uncertainty regarding whether the underlying mechanism of the stroke influences these outcomes [7, 8]. A new individual participant data meta-analysis (a high-level statistical synthesis that combines raw data from every person in multiple studies) now examines how specific stroke etiologies affect the risk-benefit profile of this combined approach. Pooled results from 2,313 patients across six randomized trials suggest that while thrombectomy alone is non-inferior at a -10% margin, it fails to meet a more stringent -5% non-inferiority threshold for functional independence (modified Rankin Scale 0-2) at 90 days [4].